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httpPercutaneous transluminal angioplasty versus
primary stenting in infrapopliteal arterial disease:
A meta-analysis of randomized trials
Ridong Wu, MD, Chen Yao, MD, PhD, Siwen Wang, MD, Xiangdong Xu, MD, Mian Wang, MD,
Zilun Li, MD, and Shenming Wang, MD, FACS, Guangzhou, China
Background: Percutaneous transluminal angioplasty (PTA) and primary stenting are commonly used endovascular
therapeutic procedures for the treatment of infrapopliteal arterial occlusive disease. However, which procedure is more
beneﬁcial for patients with infrapopliteal arterial occlusive disease is unknown.
Methods and Results: We performed a meta-analysis, searching PubMed, EMBASE, the Cochrane Central Register of
Controlled Trials, ISI Web of Knowledge, and relevant websites without language or publication date restrictions for
randomized trials that compared primary stenting with PTA in patients with infrapopliteal arterial occlusive disease.
The keywords were “stents,” “angioplasty,” “infrapopliteal,” “tibial arteries,” and “below knee.” We selected immediate
technical success, primary and secondary patency, limb salvage, and patient survival as the outcomes of this meta-analysis.
On the basis of the inclusion criteria, we identiﬁed six prospective randomized trials. One-year outcomes did not show any
signiﬁcant differences between the PTA and primary stenting groups, respectively: technical success (93.3% vs 96.2%;
odds ratio [OR], 0.59; 95% conﬁdence interval [CI], 0.24-1.47; P [ .25), primary patency (57.1% vs 65.7%; OR, 0.95;
95% CI, 0.35-2.58; P[ .92), secondary patency (73.5% vs 57.6%; OR, 2.08; 95% CI, 0.81-5.34; P[ .13), limb salvage
(82.2% vs 87.5%; OR, 0.64; 95% CI, 0.29-1.41; P [ .27), and patient survival (84.0% vs 87.5%; OR, 0.79; 95% CI,
0.40-1.55; P [ .49).
Conclusions: For infrapopliteal arterial occlusive disease, primary stenting has the same 1-year beneﬁts as PTA. There is
insufﬁcient evidence to support the superiority of either method. Primary stenting is associated with a trend toward
higher primary patency and lower secondary patency. Further large-scale prospective randomized trials should produce
more reliable results. (J Vasc Surg 2014;59:1711-20.)Infrapopliteal arterial occlusive disease afﬂicts
numerous patients with pain at rest, ischemic ulceration,
or gangrene.1,2 Critical limb ischemia (CLI) mainly results
from this disease. In general, patients suffering from CLI
have many comorbidities, such as diabetes mellitus and
end-stage renal disease, and often have high morbidity,
mortality, and consumption of health care and social care
resources.3 Therefore, effectual management is urgently
required for patients with CLI.
With the rapid improvements in endovascular instru-
ments and experience of physicians, endovascular therapy
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angioplasty (PTA) or primary stenting is the most
commonly used endovascular therapy for this disease, espe-
cially during the initial onset of CLI. Currently, PTA is
considered an effective treatment because of its minimal
invasiveness, shortened hospitalization time, and accept-
able patency rate.4 However, the application of PTA is
limited because of low procedural success, complications
associated with the endovascular procedure, and relatively
high restenosis rate.5,6 Primary stenting, especially the use
of dedicated stents that are specially designed for the
infrapopliteal arteries, is being chosen more often to treat
CLI due to infrapopliteal arterial disease. However, the
role of stenting in the infrapopliteal arteries is still
debated. The major concerns are the risks of fracture,
restenosis, and thrombosis. Thus, treating infrapopliteal
arterial occlusive disease remains a challenge for physi-
cians. In recent years, several randomized studies have
assessed the safety and efﬁcacy of PTA vs primary stenting
for CLI. However, the conclusions from these studies
remain inconsistent, contributing to the ongoing
controversy.
On the basis of this background, we performed this
meta-analysis to assess the overall outcomes from all1711
Fig 1. Flow chart of the literature search according to the Preferred Reporting Item for Systematic Reviews and Meta-
Analyses (PRISMA) statement.
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stenting for infrapopliteal arterial occlusive disease.
METHODS
Eligibility criteria. We established a prespeciﬁed
protocol for this meta-analysis. Eligible trials should fulﬁll
the following criteria: (1) prospective randomized trial;
(2) comparing PTA and primary stenting in infrapopliteal
arterial occlusive disease; (3) minimum follow-up of
6 months; (4) intention-to-treat analysis; and (5) reporting
at least one of the following outcomes: technical success,
primary patency (at 6 or 12 months), secondary patency (at
6 or 12 months), limb salvage (at 6 or 12 months), and
patient survival (at 6 or 12 months). We excluded reviews
and studies that did not provide data to calculate summary
statistics. Studies with incomplete data for demographic or
clinical variables were still included.
Information sources and search strategy. We per-
formed a systematic search of the literature according to
the Preferred Reporting Item for Systematic Reviews and
Meta-Analyses (PRISMA) statement.7 The search was
applied to PubMed, EMBASE, the Cochrane Central Reg-
ister of Controlled Trials, ISI Web of Knowledge, and other
relevant websites without language or publication date re-
strictions. Experts of this ﬁeld were consulted, and profes-
sional inquiries were obtained. Themedical subject headings
and keywords used to identify relevant articles were “stents,”
“angioplasty,” “infrapopliteal,” “tibial arteries,” and “below
knee.” Themost recent search was performed in June 2013.
Study selection and assessment of risk of bias. One
author screened the studies by title and abstract for inclu-
sion. Identiﬁed articles were assessed independently byanother author to conﬁrm their eligibility. Those studies
that qualiﬁed for full-text review were reviewed by two
independent reviewers for inclusion in the analysis. The risk
of bias was evaluated in accordance with the Cochrane
Handbook for Systematic Reviews of Interventions8 on the
basis of the following methodologic items: sequence gen-
eration, allocation concealment, blinding (participants,
personnel, and outcome assessors), incomplete outcome
data, selective outcome reporting, and other sources of
bias. Any disagreements between the reviewers were arbi-
trated by discussion with the entire group.
Outcome variables. On the basis of the Society for
Vascular Surgery/American Association for Vascular Sur-
gery reporting standards for endovascular procedures,9
we chose immediate technical success, primary and sec-
ondary patency, limb salvage, and patient survival as the
outcomes of this meta-analysis.
Data extraction. A database sheet was developed,
tested in three randomly selected studies, and then reﬁned
accordingly. We tried to collect all possible relevant informa-
tion.One author extracted the data from the included studies,
and another author double-checked the extracted data. The
data abstracted included (1) clinical and demographic char-
acteristics (age, male gender, diabetes mellitus, coronary ar-
tery disease, chronic kidney disease, smoking, hypertension,
dyslipidemia, and angiographic follow-up) and (2) primary
and secondary outcomes (technical success, loss to follow-up,
primary patency, secondary patency, clinical improvement,
limb salvage, and patient survival). Incomplete data were not
pursued with the study authors.
Statistical analysis. The statistical analyses were per-
formed on an intention-to-treat basis with use of
Table I. Bias risk assessment for six randomized trials using the Cochrane Collaboration’s toola
Domain Rand 2006 Bosiers 2009 Randon 2010 Brodmann 2011 Rand 2011 Scheinert 2012
Sequence
generation
Yes [Numbered
envelopes]
Yes [Using a
computer
random
number
generator]
Yes [Computer-
generated
randomization
sequence]
Yes [Computer-
generated list]
Unclear
[Insufﬁcient
information
about the
sequence
generation]
Yes [Numbered
envelope
system]
Allocation
concealment
Unclear
[Insufﬁcient
information]
Yes [Numbered
sealed
envelopes]
Yes [Numbered
sealed
envelopes]
Yes [Numerated
closed
envelopes]
Unclear
[Insufﬁcient
information]
Unclear
[Insufﬁcient
information]
Blinding of
participants,
personnel, and
outcome
assessors
Yes [Incomplete
blinding, but
the outcome
and the
outcome
measurement
are not likely to
be inﬂuenced]
Yes [Physicians
and patients
were unaware
of the
treatment
group
assignment]
Yes [Blinding of
participants
and key study
personnel
ensured;
unlikely that
the blinding
could have
been broken ]
Yes [The blinding
was warranted
because of
sealed
envelopes]
Unclear
[Insufﬁcient
information]
Unclear
[Insufﬁcient
information]
Incomplete
outcome data
Yes [Reasons for
missing
outcome data
unlikely to be
related to true
outcome]
Yes [Reasons for
missing
outcome data
unlikely to be
related to true
outcome]
Yes [No missing
outcome data]
Yes [Reasons for
missing
outcome data
unlikely to be
related to true
outcome]
Yes [Reasons for
missing
outcome data
unlikely to be
related to true
outcome]
Yes [Reasons for
missing
outcome data
unlikely to be
related to true
outcome]
Selective
outcome
reporting
Yes [Outcomes
were
predeﬁned in
the method
section of the
trial ]
Yes [Outcomes
were
predeﬁned in
the method
section of the
trial ]
Yes [All of the
interested
outcomes have
been reported]
Yes [Outcomes
were
predeﬁned in
the method
section of the
trial ]
No [One or more
outcomes of
interest are
reported
incompletely ]
Yes [All of the
interested
outcomes have
been reported]
Other sources of
bias
Unclear
[Insufﬁcient
information]
Unclear
[Insufﬁcient
information]
Unclear
[Insufﬁcient
information]
Unclear
[Insufﬁcient
information]
Unclear
[Insufﬁcient
information]
Unclear
[Insufﬁcient
information]
aExplanation of judgment is provided in brackets. Yes indicates low risk of bias, no indicates a high risk of bias, and unclear indicates unknown risk of bias.
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tion) and Stata 11 statistical software (StataCorp, College
Station, Tex). The odds ratio (OR) and 95% conﬁdence
interval (CI) were used as the summary statistics. Hetero-
geneity between studies was examined by the c2 test
and inconsistency (I2) statistic. P values < .1 indicated
signiﬁcant heterogeneity. I2 values <25% indicated low
heterogeneity, 25% to 50% indicated moderate heteroge-
neity, and >50% indicated high heterogeneity. The pooled
ORs and 95% CI were calculated by the Mantel-Haenszel
(M-H) ﬁxed-effects model, unless signiﬁcant heterogene-
ity existed, in which case the random-effects model was
used. Publication bias was assessed by the funnel plot,
Egger test, and Begg test. Finally, a sensitivity analysis was
conducted to determine the potential inﬂuence of each
study on the overall meta-analysis estimates. This analysis
was conducted by recalculating the summary outcome es-
timates, omitting one study at a time.
RESULTS
Study selection. We screened the abstracts of 265 sci-
entiﬁc records for potential inclusion in this meta-analysis.
A detailed ﬂow diagram of the literature search is shown in
Fig 1. Of these records, 252 citations were irrelevant orincomplete and were excluded from the next stage of
analysis. Thus, 13 studies were assessed for eligibility,
and the full-text publications were analyzed. Of these
publications, seven full-text articles were excluded because
the inclusion criteria were not met. Finally, six prospective
randomized trials were included in the meta-analysis.
Risk of bias. We assessed the bias risk of the included
trials using the Cochrane Collaboration’s tool (Table I). All
included trials were published prospective randomized
clinical trials. The sequence generation method was
described adequately and indicated a low risk of bias in all
trials except one. The methods of allocation concealment,
blinding, and incomplete outcome data were described in
almost half of the trials, which indicated a low risk of bias.
Most of the trials reported outcomes in a predeﬁned way in
the methods sections, which indicated a low risk of bias. In-
formation on other sources of bias was not described in detail
in most of the trials. Losses to follow-up were reported in all
trials. Intention-to-treat analysis was used in all the trials.
Baseline characteristics. The main demographic and
clinical features of the included trials are shown in
Table II. The primary and secondary outcomes of the
selected studies are presented in Table III. The enrolled
patients were predominantly men, elderly, and with
Table II. Main features of included trials
Rand 2006 Bosiers 2009 Randon 2010
PTA (n ¼ 27) Stent (n ¼ 24) PTA (n ¼ 57) Stent (n ¼ 60) PTA (n ¼ 22) Stent (n ¼ 16)
Age, years 72 72 73.1 6 8.5 74.7 6 7.8 72 6 10 72 6 9
Male gender NA NA 41 (71.9%) 31 (51.7%) 14 (63.6%) 6 (37.5%)
DM 19 (70%) 16 (67%) 39 (68.4%) 43 (71.7%) 12 (55%) 10 (63%)
CAD 11 (41%) 9 (38%) NA NA 18 (82%) 12 (75%)
CKD 3 (11%) 5 (21%) NA NA 12 (55%) 5 (31%)
Smoking 17 (63%) 14 (58%) 26 (45.6%) 24 (40%) 4 (18%) 1 (6%)
Hypertension NA NA 51 (89.%) 51 (85%) 22 (100%) 16 (100%)
Dyslipidemia NA NA 35 (61.4%) 32 (53.3%) 9 (41%) 7 (44%)
Type of balloon/stent Non-drug eluting Carboﬁlm coated Non-drug eluting Absorbable metal Non-drug eluting Bare metal
Lesion length, mm 24.0 12.0 6 5.0 10.6 6 4.9 NA NA
Inclusion criteria Fontaine III and IV; stenosis >70%
or occlusion; lesions #3, lesion
length #3 cm; cumulative lesion
length #9 cm
Rutherford 4 and 5; stenosis >50%
or occlusion; life expectancy
>6 months; vessel diameter
3-3.5 mm
Fontaine III and IV; Rutherford 4
to 6; stenosis>70% or occlusion
Exclusion criteria Inﬂow or outﬂow obstruction;
coagulopathy; peptic ulcer;
inﬂammatory vascular disease
Inﬂow obstruction; previous
treatment; allergy to antiplatelet or
anticoagulant; participation in
another clinical trial; pregnant;
mentally ill or retarded
Inﬂow obstruction; acute limb
ischemia; myocardial infarction;
blue toe syndrome; inability to
ambulate
Angiographic follow-
up/time
Yes/6 months Yes/6 months Yes/3, 6, 12, 18, 24 months
CAD, Coronary artery disease; CKD, chronic kidney disease; DM, diabetes mellitus; DVT, deep venous thrombosis; NA, not reported; PTA, percutaneous
transluminal angioplasty.
Table III. Primary and secondary end points
Rand 2006 Bosiers 2009 Randon 2010
PTA Stent PTA Stent PTA
Technical success 26/27 (96.3%) 23/24 (95.8%) NA NA 20/22 (90.9%)
Lost to follow-up 7/27 (25.9%) 7/24 (19.2%) 17/57 (29.8%) 22/60 (36.7%) 0/22 (0%)
Primary patency at 6 months 12/20 (61.1%) 14/17 (83.7%) 35/40 (88.1%) 30/37 (80.2%) 17/22 (76%)
Primary patency at 12 months NA NA NA NA 15/22 (66%)
Secondary patency at 12 months NA NA NA NA 17/22 (79.5%)
Clinical improvement at 12 months NA NA NA NA NA
Limb salvage at 6 months 20/21 (95%) 17/19 (92%) 53/57 (92.4%) 53/60 (87.6%) 20/22 (90%)
Limb salvage at 12 months NA NA NA NA 20/22 (90%)
Patient survival at 6 months 26/27 (96.3%) 23/24 (95.8%) 53/57 (92.5%) 55/60 (91.3%) 21/22 (94%)
Patient survival at 12 months NA NA NA NA 15/22 (69.3%)
NA, Not reported; PTA, percutaneous transluminal angioplasty.
aData at 9 months.
bData at 3 months.
JOURNAL OF VASCULAR SURGERY
1714 Wu et al June 2014coronary artery disease risk factors such as diabetes mel-
litus, chronic kidney disease, smoking, hypertension, and
dyslipidemia. Within each trial, the baseline characteristics
were similar between the PTA and stent groups. A total of
548 patients constituted our ﬁnal study population, with
284 patients (51.8%) treated by PTA and 264 patients
(48.2%) treated by primary stenting. The number of
participants in the included studies varied from 38 to 200
in the randomized trials. Patients from the study of Rand
2006 were not included in the study of Rand 2011, and
patients from the study of Bosiers 2009 were also not
included in the study of Scheinert 2012. The disease
severity was almost the same, and the main inclusion
criteria were Fontaine stages III and IV or Rutherfordstages 3 to 5. Four studies reported patients with CLI.10-
13 No signiﬁcant discrepancies in these criteria were
identiﬁed among the studies. The main exclusion criteria
in the included trials were inﬂow or outﬂow obstruction,
hematologic diseases, and short life expectancy. The type
of stents used in the endovascular procedures varied
among the studies and included Carboﬁlm-coated
stents,14 absorbable metal stents,10 self-expandable
stents,11 balloon-expandable stents,12 dedicated stents
for below-the-knee arteries,13 and sirolimus-eluting
stents.15 The types of balloons used in PTA in these tri-
als are all non-drug-eluting balloons. The primary patency
rate was deﬁned as restenosis of more than 50% after
revascularization or absence of clinically driven target
Brodmann 2011 Rand 2011 Scheinert 2012
PTA (n ¼ 33) Stent (n ¼ 21) PTA (n ¼ 44) Stent (n ¼ 44) PTA (n ¼ 101) Stent (n ¼ 99)
68.9 6 2.9 74.9 6 1.3 72.1 6 9.5 71.4 6 8.0 74.3 6 8.2 72.4 6 9.4
13 (39.4%) 12 (57.1%) 28 (63.6%) 30 (68.2%) 76 (75.2%) 67 (67.7%)
24 (72.7%) 16 (76.2%) 34 (75.6%) 35 (79.5%) 65 (64.4%) 64 (64.6%)
29 (87.9%) 18 (85.7%) NA NA 45 (44.6%) 45 (45.5%)
NA NA NA NA NA NA
8 (24.2%) 7 (33.3%) NA NA 27 (26.3%) 38 (38.4%)
27 (81.8%) 19 (90.5%) NA NA 92 (91.1%) 89 (89.9%)
6 (18.2%) 14 (66.7%) NA NA 69 (68.3%) 77 (77.6%)
Non-drug eluting Silicon carbide coated Non-drug eluting Turbostatic carbon
coated
Non-drug eluting Sirolimus coated
78.48 27.86 20.7 6 20.1 21.0 6 12.2 26.8 6 21.3 26.9 6 20.9
Rutherford 4 to 6; stenosis >70%,
cumulative lesion length #12 cm; life
expectancy $12 months
Rutherford 4 and 5; stenosis $50%; lesion
length #4.5 cm; vessel diameter 2-4 mm
Rutherford 3 to 5
Inﬂow obstruction; previous treatment;
allergy to clopidogrel or aspirin;
indication for oral anticoagulation;
participation in another clinical trial
Inﬂow or outﬂow obstruction; previous
treatment; underlying disease (eg, renal
failure or bleeding disorders)
Inﬂow or outﬂow obstruction;
thrombolysis within 72 hours; DVT;
thrombus; life expectancy
<12 months; intolerance to
antiplatelet; kidney dysfunction
Yes/3, 6, 12 months Yes/3 months, 9 months Yes/6 weeks, 6 months, 12 months
Randon 2010 Brodmann 2011 Rand 2011 Scheinert 2012
Stent PTA Stent PTA Stent PTA Stent
14/16 (87.5%) NA NA 42/44 (95.5%) 44/44 (100%) 93/101 (92.1%) 95/99 (95.5%)
0/16 (0%) 6/33 (18.2%) 4/21 (19.0%) 18/44a (40.9%) 23/44a (52.3%) 18/101 (17.8%) 20/99 (20.2%)
13/16 (80%) 16/27 (60.7%) 9/17 (52.6%) NA NA NA NA
9/16 (56%) 13/27 (48.1%) 6/17 (35.3%) 17/26a (65.4%) 16/21a (76.2%) 44/77 (57.1%) 54/72 (75%)
10/16 (64%) 19/27 (70.4%) 9/17 (52.9%) NA NA NA NA
NA 22/27 (81.5%) 11/17 (64.7%) 14/24a (58.3%) 9/19a (47.4%) 51/76 (67.1%) 54/71 (76.1%)
15/16 (91.7%) NA NA 28/32b (87.5%) 27/33b (81.8%) NA NA
15/16 (91.7%) NA NA 19/26a (73%) 11/21a (52.4%) 68/85 (80%) 69/80 (86.3%)
13/16 (79.8%) NA NA 41/44b (93.2%) 39/44b (88.6%) NA NA
12/16 (74.7%) 27/33 (81.8%) 18/21 (85.7%) 39/44a (88.6%) 39/44a (88.6%) 89/101 (88.1%) 89/99 (89.9%)
Table II. Continued.
Table III. Continued.
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freedom from repeated angioplasty until recurrence of
symptoms.
Outcomes
The meta-analysis outcomes in the entire study popula-
tion are summarized in the Table IV. The random-effects
model was used only in the analysis of primary patency at
12 months because of the heterogeneity that existed.
Begg test and Egger test validated the absence of publica-
tion bias. The eight summary ORs of combined parameters
were of no statistical signiﬁcance.
Technical success. Four trials11,13-15 evaluated the
technical success of PTA vs stenting. The incidence of
combined technical success was 93.3% in the PTA groupand 96.2% in the stent group. There was no signiﬁcant
difference between the two groups, and the summary OR
was 0.59 (95% CI, 0.24-1.47; Z ¼ 1.14; P ¼ .25). There
was low heterogeneity across the trials (c2 ¼ 1.51; P ¼ .68;
I2 ¼ 0%). The funnel plot, Begg test (Z ¼ 0.34; P ¼ .743),
and Egger test (t ¼ 0.19; P ¼ .869) indicated no publi-
cation bias among the trials (Fig 2).
Primary patency. Four trials10,11,13,14 evaluated the
primary patency at 6 months for PTA vs stenting. The
incidence of combined primary patency at 6 months was
73.4% in the PTA group and 75.9% in the stent group.
There was no signiﬁcant difference between the two
groups, and the summary OR was 0.94 (95% CI, 0.48-1.8;
Z ¼ 0.18; P ¼ .86). There was low heterogeneity across the
trials (c2 ¼ 2.94; P ¼ .40; I2 ¼ 0%). The funnel plot, Begg
Table IV. Summary meta-analysis of outcomes in the entire study population
Outcome measure No. of studies Meta-analysis model OR (95% CI) P Publication bias (P)
Technical success 4 Fixed effects 0.59 (0.24-1.47) .25 .869
Primary patency at 6 months 4 Fixed effects 0.94 (0.48-1.83) .86 .202
Primary patency at 12 months 3 Random effects 0.95 (0.35-2.58) .92 .453
Patient survival at 6 months 3 Fixed effects 0.96 (0.29-3.18) .95 .805
Patient survival at 12 months 3 Fixed effects 0.79 (0.40-1.55) .49 .199
Limb salvage at 6 months 3 Fixed effects 1.55 (0.56-4.29) .40 .741
Limb salvage at 12 months 2 Fixed effects 0.64 (0.29-1.41) .27 NA
Secondary patency at 12 months 2 Fixed effects 2.08 (0.81-5.34) .13 NA
CI, Conﬁdence interval; NA, not applicable; OR, odds ratio.
Fig 2. Forest plot of the estimated individual and overall effect of the technical success at 12 months between
percutaneous transluminal angioplasty (PTA) and primary stenting groups. CI, Conﬁdence interval; M-H, Mantel-
Haenszel.
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.202) indicated no publication bias among the trials
(Fig 3).
Three trials11,12,15 evaluated the primary patency at
12 months for PTA vs stenting. The incidence of combined
primary patency at 12 months was 57.1% in the PTA group
and 65.7% in the stent group. There was high heterogene-
ity across the trials (c2 ¼ 5.17; P ¼ .08; I2 ¼ 61%). There-
fore, we used a random-effects model to calculate the
combined parameters. There was no signiﬁcant difference
between the two groups, and the summary OR was 0.95
(95% CI, 0.35-2.58; Z ¼ 0.10; P ¼ .92). The funnel
plot, Begg test (Z ¼ 0.00; P ¼ 1.00), and Egger test
(t ¼ 1.16; P ¼ .453) indicated no publication bias among
the trials (Fig 3).
Secondary patency. Only two trials11,12 evaluated the
secondary patency at 12 months for PTA vs stenting. The
incidence of combined secondary patency at 12 months
was 73.5% in the PTA group and 57.6% in the stent group.
There was no signiﬁcant difference between the two
groups, and the summary OR was 2.08 (95% CI, 0.81-
5.34; Z ¼ 1.52; P ¼ .13). There was low heterogeneity
across the trials (c2 ¼ 0.00; P ¼ .97; I2 ¼ 0%) (Fig 4). No
available data were found to evaluate secondary patency at
6 months in these trials.
Limb salvage. Three trials10,11,14 evaluated limb
salvage at 6 months for PTA vs stenting. The incidence ofcombined limb salvage at 12 months was 93.0% in the PTA
group and 89.5% in the stent group. There was no signif-
icant difference between the two groups, and the summary
OR was 1.55 (95% CI, 0.56-4.29; Z ¼ 0.85; P ¼ .40).
There was low heterogeneity across the trials (c2 ¼ 0.58;
P ¼ .75; I2 ¼ 0%). The funnel plot, Begg test (Z ¼ 0.00;
P ¼ 1.000), and Egger test (t ¼ 0.43; P ¼ .741) indi-
cated no publication bias among the trials (Fig 5).
Only two trials11,15 evaluated limb salvage at 12 months
for PTA vs stenting. The incidence of combined limb
salvage at 12 months was 82.2% in the PTA group and
87.5% in the stent group. There was no signiﬁcant difference
between the two groups, and the summary OR was 0.64
(95% CI, 0.29-1.41; Z ¼ 1.11; P ¼ .27). There was low het-
erogeneity across the trials (c2 ¼ 0.00; P ¼ .97; I2 ¼ 0%).
Patient survival. Three trials10,11,14 evaluated the
patient survival at 6 months for PTA vs stenting. The
incidence of combined patient survival at 6 months was
94.3% in the PTA group and 94.8% in the stent group. There
was no signiﬁcant difference between the two groups, and
the summary OR was 0.96 (95% CI, 0.29-3.18; Z ¼ 0.06;
P ¼ .95). There was moderate heterogeneity across the trials
(c2 ¼ 3.30; P ¼ .19; I2 ¼ 39%). The funnel plot, Begg test
(Z ¼ 0.00; P ¼ 1.000), and Egger test (t ¼ 0.32; P ¼ .805)
indicated no publication bias among the trials (Fig 6).
Three trials11,12,15 evaluated the patient survival at
12 months for PTA vs stenting. The incidence of combined
Fig 3. Forest plots of the estimated individual and overall effect of the primary patency between percutaneous
transluminal angioplasty (PTA) and primary stenting groups at 6 months (A) and 12 months (B). CI, Conﬁdence
interval; M-H, Mantel-Haenszel.
Fig 4. Forest plot of the estimated individual and overall effect of the secondary patency at 12 months between
percutaneous transluminal angioplasty (PTA) and primary stenting groups. CI, Conﬁdence interval; M-H, Mantel-
Haenszel.
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and 87.5% in the stent group. There was no signiﬁcant dif-
ference between the two groups, and the summary OR was
0.79 (95% CI, 0.40-1.55; Z ¼ 0.69; P ¼ .49). There was
low heterogeneity across the trials (c2 ¼ 0.04; P ¼ .98;
I2 ¼ 0%). The funnel plot, Begg test (Z ¼ 0.00; P ¼
1.000), and Egger test (t ¼ 3.10; P ¼ .199) indicated
no publication bias among the trials (Fig 6).
Sensitivity analysis
Sensitivity analyses were performed to determine the
inﬂuence of a single study on the overall effect estimate.
The pooled estimates for technical success, primary
patency, secondary patency, limb salvage, and patient sur-
vival were recalculated and omitted one study at a time.
The results showed that no single study signiﬁcantlyinﬂuenced the summary ORs of the end points because
every outcome point estimate was within the initial 95%
CI when one study was omitted at a time.
DISCUSSION
The continuous advancement of endovascular technol-
ogy and equipment has revolutionized the treatment of
lower extremity arterial occlusive disease in the last de-
cades.16-18 Physicians should ﬁnd an optimal treatment
strategy through comparing the therapeutic effects of this
technology and equipment and then propagate the use of
it. Infrapopliteal intervention is different from intervention
for more proximal arteries in several aspects.19 Arteries
below the knee are smaller in caliber and often have severe
calciﬁcation, especially in patients with CLI.20,21 CLI asso-
ciated with infrapopliteal arteries often involves long
Fig 5. Forest plots of the estimated individual and overall effect of the limb salvage between percutaneous transluminal
angioplasty (PTA) and primary stenting groups at 6 months (A) and 12 months (B). CI, Conﬁdence interval; M-H,
Mantel-Haenszel.
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Only 20% to 30% of cases have simple focal lesions and
good runoff.22 Patients who are elderly, suffer from severe
comorbidities, and have a limited life expectancy will have
the worst prognosis.23-25 Therefore, the endovascular
treatment of the infrapopliteal arteries remains a challenge
for physicians. The published data have proved that infra-
popliteal PTA is an effective treatment in patients with
CLI.26 It can be used to feasibly and safely treat these pa-
tients, with satisfactory clinical results.26,27 PTA in small-
caliber below-the-knee arteries is also accompanied by
elastic recoil, arterial remodeling, and dissection, which
are caused by technical failure and other complications.3
Stent implantation, especially of dedicated stents, may
reduce these complications and theoretically improves the
patency rate.28 However, its application in the infrapopli-
teal arteries is still debated. The treatment outcomes of
stent implantation in this arterial segment have not reached
the initial expectations. The main challenges are the risks of
fracture, restenosis, thrombosis, and inﬂammatory and pro-
liferative responses of the arterial wall.29,30 Primary stenting
means stenting is the ﬁrst strategy in the treatment of infra-
popliteal arterial occlusive diseases, not after failed angio-
plasty. Until now, a consensus on the beneﬁts of PTA
over primary stenting has not been reached. Several recent
prospective randomized studies compared the outcomes of
PTA vs primary stenting in the treatment of infrapopliteal
arterial occlusive disease, but the results were inconsistent.
In this article, we focused on which therapeutic mea-
sure is better as the ﬁrst choice for this kind of disease, an-
gioplasty or primary stenting. To obtain subjective and
accurate results, we involved only randomized trials inour analysis. The present meta-analysis of randomized trials
was conducted to investigate the outcomes of PTA vs pri-
mary stenting in patients undergoing revascularization for
infrapopliteal arterial occlusive disease and provided level
I evidence-based recommendation about the controversy
regarding which method is the optimal ﬁrst-line treatment
in such patients. The results showed that primary stenting
did not signiﬁcantly improve outcomes at 12 months, as
expressed by technical success, primary patency, secondary
patency, limb salvage, and patient survival. There are
several explanations for the ﬁndings of the present analysis.
First, the variability of stent types may affect the pooled
outcomes. Six different types of stents were used in the
included trials. Different stent types may have different
therapeutic results in the same disease.31,32 Some studies
demonstrated favorable 1-year results with primary stent-
ing compared with PTA, but other studies did not produce
similar results. This difference may have led to the insignif-
icant combined results of the comparisons between the two
endovascular procedures. Further trials are needed to focus
on a single stent, such as one dedicated for use in infrapo-
pliteal arteries, and then to compare the results of primary
stenting vs PTA. A meta-analysis based on such trials may
have more authentic results.
Second, our current analysis included six studies with
548 participants. For one of the parameters, not all studies
provided information. Some results were based on only
two trials with fewer than 200 participants. Thus, the total
number of participants enrolled in this meta-analysis was
relatively small, which may lead to some bias in the pooled
results. The primary patency rates of PTA and primary
stenting were 57.1% and 65.7%, respectively. The
Fig 6. Forest plot of the estimated individual and overall effect of the patent survival between percutaneous trans-
luminal angioplasty (PTA) and primary stenting groups at 6 months (A) and 12 months (B). CI, Conﬁdence interval;
M-H, Mantel-Haenszel.
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tively. Although these differences are not signiﬁcant, pri-
mary stenting appeared to be associated with a trend
toward higher primary patency and lower secondary
patency. Compared with primary stenting, the technical
success of revascularization was higher in patients after
PTA. Therefore, the secondary patency might be higher.
Trials with a larger number of enrolled participants might
be able to conﬁrm this result. Meanwhile, the weight per-
centage of each study in the analysis was unbalanced. In the
pooled analysis of primary patency at 12 months, the
weight percentage of Scheinert’s study, which was 76.8%,
was much greater than that of the other studies.15 This
imbalance may be the source of heterogeneity for this
outcome. Thus, the results of this analysis were limited.
In the future, large-scale prospective randomized trials
are expected to obtain more reliable results.
Third, the duration of follow-up was relatively short in
the six included trials. All six trials had only 12-month
follow-ups; thus, the long-term results remain unknown.
Differences in some outcome parameters that were not sig-
niﬁcant at 12 months might be signiﬁcant at more than
12 months. Further trials should prolong the follow-up
time and evaluate the long-term efﬁcacy of these two endo-
vascular procedures.
Fourth, the length of lesions might inﬂuence the thera-
peutic effect. In ﬁve of six trials involved in our meta-
analysis, there was no statistically signiﬁcant difference
between the PTAgroup and the stenting group in the length
of lesions. Only in the trial of Brodmann 2011 was thelength of lesions in the PTA group signiﬁcantly longer
than in the stenting group. However, the results show that
stenting does not outstrip the beneﬁt of PTA.12 Further
study is needed to investigate the role of lesion length in
the treatment of infrapopliteal arterial occlusive diseases.
Finally, the outcome parameters used to evaluate the
anatomic and clinical results in the meta-analysis may not
sufﬁciently substantiate the clinical effects. Some additional
factors, such as freedom from target lesion revasculariza-
tion, should be introduced to assess the clinical outcomes.
Furthermore, in treating complicated lesions, such as
multilevel or multilocal disease in CLI patients, the perfor-
mance of PTA and primary stenting should be further eval-
uated. Because of these inherent limitations, conclusions
about the impact of this meta-analysis on clinical practice
should be made carefully.
CONCLUSIONS
This analysis demonstrated that PTA and primary
stenting have the same safety and efﬁcacy for the treatment
of CLI leading to infrapopliteal arterial occlusive disease.
The comparisons of the 12-month results between the
two treatment groups related to technical success, primary
patency, secondary patency, limb salvage, and patient sur-
vival did not reveal any signiﬁcant differences. Primary
stenting is associated with a trend toward higher primary
patency and lower secondary patency. There was insufﬁ-
cient evidence to demonstrate that one treatment is better
than the other. Further multicenter and prospective ran-
domized trials evaluating the outcomes of PTA and
JOURNAL OF VASCULAR SURGERY
1720 Wu et al June 2014primary stenting are required to assess the efﬁcacy of the
two treatments in patients with infrapopliteal arterial occlu-
sive disease.
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